New antibody weapon targets stubborn blood cancers

NCT ID NCT04606433

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study is testing an experimental drug called GNC-038, a quad-specific antibody designed to attack cancer cells from multiple angles. It is for people with relapsed or refractory non-Hodgkin lymphoma or acute lymphoblastic leukemia who have not responded to other treatments. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GNC-038 (a quad-specific antibody injection)
What this could lead to: If successful, this could lead to a new treatment option for people with blood cancers that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 47 participants, so it is primarily testing safety and dosing. The antibody may not work well or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia metastatic malignant neoplasm non-Hodgkin lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, China
Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China
Hematology Hospital, Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, 300000, China
Nanfang Hospital of Southern Medical University

Guangzhou, Guangdong, China
Peking University Third Hospital

Beijing, Beijing Municipality, China
Shanghai Tongji Hospital

Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China
The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China
The Second Hospital of Anhui Medical University

Hefei, Anhui, China
Xiangya Hospital Central South University

Changsha, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.